Greenwich LifeSciences Announces Receipt of Nasdaq Notice Regarding Late Form 10-K Filing

Greenwich LifeSciences (Nasdaq: GLSI) received a notice from Nasdaq on April 16, 2026, for noncompliance with Nasdaq Listing Rule 5250(c)(1) because it has not yet filed its Annual Report on Form 10-K for the fiscal year ended December 31, 2025.

Rhea-AI Summary

Greenwich LifeSciences (Nasdaq: GLSI) received a notice from Nasdaq on April 16, 2026, for noncompliance with Nasdaq Listing Rule 5250(c)(1) because it has not yet filed its Annual Report on Form 10-K for the fiscal year ended December 31, 2025.

The notice does not affect the current listing or trading of GLSI common stock. The company says it will file the Form 10-K as soon as possible, coordinating with two auditors who are each responsible for their respective periods in 2024 and 2025.

Positive

• Common stock continues trading on Nasdaq Capital Market
• Company plans to file the Form 10-K as soon as possible
• Two auditors assigned, each responsible for specific periods

Negative

• Not currently in compliance with Nasdaq Rule 5250(c)(1)
• Annual Report on Form 10-K for FY 2025 remains unfiled as of April 16, 2026

Argus Apr 23 session

-5.09% close to close 0.5x rel. volume Open Argus

Details

News Market Reaction – GLSI

On Apr 23, the first trading day after this news, GLSI closed 5.09% below the previous close.

Data tracked by StockTitan Argus for the Apr 23 session.

Key Figures

Nasdaq notice date: April 16, 2026 Form 10-K period: Fiscal year ended December 31, 2025

Nasdaq notice date

April 16, 2026

Date Nasdaq notified GLSI of late Form 10-K

Form 10-K period

Fiscal year ended December 31, 2025

Annual report that has not yet been filed

Historical Context

5 past events · Latest: Apr 20

5 events

1. Apr 20

   Clinical data update

   24h Move

   -11.6%

   Phase III FLAMINGO-01 open-label immune response data presented at AACR 2026.

2. Apr 14

   Financing update

   24h Move

   -5.3%

   ATM-driven cash raise exceeding Q1 2026 cash burn for trial funding.

3. Apr 07

   Patent expansion

   24h Move

   +2.2%

   New patent claims potentially doubling GP2 market to 88,000 patients/year.

4. Mar 19

   Trial site expansion

   24h Move

   -3.1%

   Addition of City of Hope network sites to FLAMINGO-01 Phase III trial.

5. Mar 18

   Conference abstracts

   24h Move

   -11.1%

   AACR 2026 abstracts on FLAMINGO-01 immune response data and study design.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

phase iii, immunotherapy, fast track, form 10-k, +2 more

6 terms

phase iii medical

"a clinical-stage biopharmaceutical company focused on its Phase III clinical trial"

A Phase III trial is the late-stage clinical study that tests whether a medical treatment works and is safe in a large group of patients, often comparing it to standard care. Think of it as a final dress rehearsal or full-scale road test before regulators decide on approval; positive or negative results strongly influence a drug maker’s chance to sell the treatment, future revenue, and investment risk.

immunotherapy medical

"GLSI-100, an immunotherapy to prevent breast cancer recurrences"

Treatment that uses or enhances the body’s immune system to detect and fight disease, most often cancers or chronic infections; think of it as training or arming the body’s own soldiers to find and destroy targets. It matters to investors because successful immunotherapies can lead to high-value drug approvals, recurring revenue from long-term treatments, and changes in competitive dynamics, while failures or safety issues in clinical trials can materially affect company valuations.

fast track regulatory

"evaluating Fast Track designated GLSI-100, an immunotherapy"

A fast track designation is a regulatory label that speeds up the review and communication between a drug developer and regulators for treatments addressing serious illnesses or unmet medical needs. For investors, it matters because it can shorten development time and reduce regulatory delays—like getting a VIP lane at the airport—raising the chance of earlier market access and potential revenue, though it does not guarantee approval.

form 10-k regulatory

"has not yet filed its Annual Report on Form 10-K for the fiscal year"

A Form 10-K is a comprehensive report that publicly traded companies are required to file annually with regulators. It provides a detailed overview of a company's financial health, operations, and risks, similar to a detailed health report. Investors use this information to assess the company's performance and make informed decisions about buying or selling its stock.

nasdaq listing rule 5250(c)(1) regulatory

"not currently in compliance with Nasdaq Listing Rule 5250(c)(1), which requires"

Nasdaq Listing Rule 5250(c)(1) requires companies listed on the Nasdaq stock exchange to promptly notify the exchange if their stock price falls below a certain minimum level, known as the "initial listing standards." This rule helps ensure that investors are aware of significant declines in a company's stock value, which could signal financial trouble or increased risk. Essentially, it helps maintain transparency and protect investors by keeping them informed about important changes in a company's stock performance.

nasdaq capital market regulatory

"continues to trade on the Nasdaq Capital Market under the symbol"

The Nasdaq Capital Market is a platform where smaller, emerging companies can list their shares for trading by investors. It provides these companies with access to funding and visibility, helping them grow, much like a local marketplace where new vendors can introduce their products to potential customers. For investors, it offers opportunities to discover early-stage companies with growth potential.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

STAFFORD, Texas, April 22, 2026 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating Fast Track designated GLSI-100, an immunotherapy to prevent breast cancer recurrences, today announced that on April 16, 2026, the Company received notification from the Listing Qualifications Department of The Nasdaq Stock Market LLC notifying the Company that, because it has not yet filed its Annual Report on Form 10-K for the fiscal year ended December 31, 2025, the Company is not currently in compliance with Nasdaq Listing Rule 5250(c)(1), which requires timely filing of periodic financial reports with the Securities and Exchange Commission. The notice has no immediate effect on the listing or trading of the Company's common stock, which continues to trade on the Nasdaq Capital Market under the symbol "GLSI."

The Company plans to file its Form 10-K for the fiscal year ended December 31, 2025 as soon as possible, working with both of its auditors where each auditor is responsible for their own periods ending in 2024 and 2025.

About Greenwich LifeSciences, Inc.

Greenwich LifeSciences is a clinical-stage biopharmaceutical company focused on the development of GP2, an immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery. GP2 is a 9 amino acid transmembrane peptide of the HER2 protein, a cell surface receptor protein that is expressed in a variety of common cancers, including expression in 75% of breast cancers at low (1+), intermediate (2+), and high (3+ or over-expressor) levels. Greenwich LifeSciences has commenced a Phase III clinical trial, FLAMINGO-01. For more information on Greenwich LifeSciences, please visit the Company's website at www.greenwichlifesciences.com and follow the Company's Twitter at https://twitter.com/GreenwichLS.

Forward-Looking Statement Disclaimer

Statements in this press release contain "forward-looking statements" that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as "anticipate," "believe," "contemplate," "could," "estimate," "expect," "intend," "seek," "may," "might," "plan," "potential," "predict," "project," "target," "aim," "should," "will," "would," or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on Greenwich LifeSciences Inc.'s current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict, including statements regarding the intended use of net proceeds from the public offering; consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. These and other risks and uncertainties are described more fully in the section entitled "Risk Factors" in Greenwich LifeSciences' Annual Report on the most recent Form 10-K for the year ended December 31, 2024, and other periodic reports filed with the Securities and Exchange Commission. Forward-looking statements contained in this announcement are made as of this date, and Greenwich LifeSciences, Inc. undertakes no duty to update such information except as required under applicable law.

Company Contact
Snehal Patel
Investor Relations
Office: (832) 819-3232
Email: info@greenwichlifesciences.com

Investor & Public Relations Contact for Greenwich LifeSciences
Dave Gentry
RedChip Companies Inc.
Office: 1-800-RED CHIP (733 2447)
Email: dave@redchip.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

Why did Nasdaq notify Greenwich LifeSciences (GLSI) on April 16, 2026?

Nasdaq notified GLSI for failing to timely file its Form 10-K for fiscal year 2025. According to the company, the notice cites noncompliance with Nasdaq Listing Rule 5250(c)(1) because the Annual Report had not yet been filed.

Is Greenwich LifeSciences (GLSI) still listed and trading after the Nasdaq notice?

Yes—GLSI common stock remains listed and trading on Nasdaq. According to the company, the notice has no immediate effect on the listing or trading of the shares on the Nasdaq Capital Market.

When will Greenwich LifeSciences (GLSI) file its Form 10-K for 2025?

The company plans to file the Form 10-K as soon as possible. According to the company, it is working with two auditors, each responsible for their respective periods in 2024 and 2025.

What does the Nasdaq notice about GLSI mean for investors?

The notice indicates noncompliance with filing requirements but does not change trading status now. According to the company, it intends to cure the filing deficiency by submitting the Form 10-K promptly.

Does the Nasdaq notice mention any immediate delisting of GLSI shares?

No, the notice does not impose an immediate delisting or suspension. According to the company, the communication from Nasdaq simply notifies GLSI of noncompliance under the listing rule.